Among adults receiving adalimumab, patients with HS had a greater risk for hospitalization due to infections than patients with PsO.

DelveInsight's AHR Agonists Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

A new treatment for a debilitating inflammatory condition which affects joints and skin has shown promising early results in ...

Sustained two-year treatment with tildrakizumab improved the psychological well-being of people with moderate to severe ...